Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118047653 | 11804765 | 3 | F | 20160713 | 20151205 | 20160722 | EXP | JP-AMGEN-JPNSP2015129880 | AMGEN | 82.00 | YR | E | F | Y | 48.50000 | KG | 20160722 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118047653 | 11804765 | 1 | PS | cinacalcet HCl | CINACALCET HYDROCHLORIDE | 1 | Oral | 25 MG, UNK | U | 21688 | 25 | MG | TABLET | ||||||
| 118047653 | 11804765 | 2 | SS | cinacalcet HCl | CINACALCET HYDROCHLORIDE | 1 | Oral | 5 MG, UNK | U | 21688 | 5 | MG | TABLET | ||||||
| 118047653 | 11804765 | 3 | SS | cinacalcet HCl | CINACALCET HYDROCHLORIDE | 1 | Oral | 100 MG, UNK | U | 21688 | 100 | MG | TABLET | ||||||
| 118047653 | 11804765 | 4 | SS | cinacalcet HCl | CINACALCET HYDROCHLORIDE | 1 | Oral | 75 MG, UNK | U | 21688 | 75 | MG | TABLET | ||||||
| 118047653 | 11804765 | 5 | SS | ADRIACIN | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous drip | UNK | 0 | ||||||||||
| 118047653 | 11804765 | 6 | SS | RITUXIMAB | RITUXIMAB | 1 | Intravenous drip | UNK | 0 | ||||||||||
| 118047653 | 11804765 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous drip | UNK | 0 | ||||||||||
| 118047653 | 11804765 | 8 | SS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous drip | UNK | 0 | INJECTION | |||||||||
| 118047653 | 11804765 | 9 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | UNK | 0 | ||||||||||
| 118047653 | 11804765 | 10 | SS | RITUXIMAB RECOMBINANT | RITUXIMAB | 1 | Intravenous drip | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 118047653 | 11804765 | 1 | Hyperparathyroidism primary |
| 118047653 | 11804765 | 5 | Diffuse large B-cell lymphoma |
| 118047653 | 11804765 | 6 | Diffuse large B-cell lymphoma |
| 118047653 | 11804765 | 7 | Diffuse large B-cell lymphoma |
| 118047653 | 11804765 | 8 | Diffuse large B-cell lymphoma |
| 118047653 | 11804765 | 9 | Diffuse large B-cell lymphoma |
| 118047653 | 11804765 | 10 | Diffuse large B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 118047653 | 11804765 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 118047653 | 11804765 | Hyperparathyroidism primary | |
| 118047653 | 11804765 | Nausea | |
| 118047653 | 11804765 | Parathyroid tumour benign |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 118047653 | 11804765 | 1 | 20140319 | 0 |